Biopharmaceutical company developing treatments for inflammatory diseases and cancer.
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Celldex Therapeutics, Inc. in the last 30 days yet.
The 2 sources with the most insights about Celldex Therapeutics, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Its hives-drug data was described as strong, though speakers questioned the urgency and scale of the medical need; the stock rallied as much as 20–30% before fading.
A speaker praised the company and its data, including a drug for hives, but the stock's 20–30% rally and subsequent fade highlighted volatility; no detailed trial or commercial analysis was provided.
Its hives-drug data was described as strong, though speakers questioned the urgency and scale of the medical need; the stock rallied as much as 20–30% before fading.
A speaker praised the company and its data, including a drug for hives, but the stock's 20–30% rally and subsequent fade highlighted volatility; no detailed trial or commercial analysis was provided.
Other assets that creators frequently mention in the same content as Celldex Therapeutics, Inc..
The most active sources covering Celldex Therapeutics, Inc. (CLDX) on Kazuha are @realmartinshkreli, @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Celldex Therapeutics, Inc. (CLDX) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Celldex Therapeutics, Inc. (CLDX) most frequently also discuss DOGE, IOVA, LRCX, INTC, AMD. See the "Discussed alongside" section above for full asset pages.